GOVERNEUR, N.Y. – Kinney Drugs has now opened both walk-ins and appointments for a second dose of seasonal COVID-19 vaccine for eligible individuals. In October, the CDC recommended that individuals aged 65 and older and those who are moderately to severely immunocompromised receive a second dose of seasonal COVID-19 vaccine two to six months after their last dose.
Patients in one or both groups who were vaccinated against COVID in the fall may now be due for a second dose. Kinney Drugs accepts walk-ins; however, appointments are encouraged to ensure the promptest service. The COVID-19 vaccine can be co-administered with all other approved vaccines.
“CDC data show the importance of vaccination to protect people who are most at risk for severe outcomes of COVID, such as older adults and anyone with an immunocompromising condition,” said John Marraffa, president of Kinney Drugs. “We know that vaccination can restore and enhance protection against those viruses that are causing infections and hospitalizations in our region, including RSV, COVID, and influenza. And flu is spiking right now, especially in older populations. So, if patients haven’t received their flu vaccine, it’s not too late for this year. As always, our pharmacists stand ready to assist with immunizations and other healthcare needs,” he added.
Kinney Drugs expands COVID-19 vaccine access for high-risk individuals
Patients in one or both groups who were vaccinated against COVID in the fall may now be due for a second dose.
Related
U.S. Drug spending up 10.2% in 2024, with weight loss drugs topping the list
Tariff concerns raise risk of shortages and higher costs.
RILA warns tariffs on pharma could hurt consumers
Industry warns of higher consumer costs, shortages, and unintended fallout from national security measures.
Global generic drugs market to reach $594.99 billion by 2031
The combination of patent cliffs, supportive policy environments, and increasing disease prevalence is creating strong growth momentum.
Lilly to expand collaboration with Purdue University
Will include a planned investment up to a $250 million to accelerate pharmaceutical innovation.
Latest
Monistat gets a new look
Monistat has refreshed its packaging with a new and improved box but kept its tried-and-true formula the same.
U.S. Drug spending up 10.2% in 2024, with weight loss drugs topping the list
Tariff concerns raise risk of shortages and higher costs.
RILA warns tariffs on pharma could hurt consumers
Industry warns of higher consumer costs, shortages, and unintended fallout from national security measures.
Retail imports to decline as Trump tariffs take hold
“We are starting to see the true impact of President Trump’s tariffs on the supply chain,” NRF Vice President for Supply Chain and Customs Policy Jonathan Gold said.